title: New targeted therapies for indolent B-cell malignancies in older patients.
abstract: Molecularly targeted agents have become an established component of the treatment of indolent B-cell malignancies (iNHL). iNHL disproportionately affects older adults, so treatments that have excellent tolerability and efficacy across multiple lines of therapy are in demand. The numbers and classes of targeted therapies for iNHL have proliferated rapidly in recent years; classes of agents that show promise for older patients with iNHL include anti-CD20 antibodies, phosphatidyl-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway inhibitors, immunomodulators, proteasome inhibitors, epigenetic modulators, and immunotherapies. Here, we review the proposed mechanisms of action, efficacy, and tolerability of novel agents for iNHL, with an emphasis on their applicability to older patients.
authors.affiliation: From the University of Louisville Brown Cancer Center, Louisville, KY; Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Maxwell M
authors.initials: MM
authors.lastname: Krem
authors.affiliation: From the University of Louisville Brown Cancer Center, Louisville, KY; Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000368:Aged; D000906:Antibodies / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D005544:Forecasting; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D015448:Leukemia, B-Cell / Q000628:therapy*; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000276:immunology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000906:Antibodies; D018951:Antigens, CD20; D018796:Immunoconjugates; D007155:Immunologic Factors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061988:Proteasome Inhibitors; C546842:MTOR protein, human; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D051058:Oncogene Protein v-akt; D058570:TOR Serine-Threonine Kinases